<DOC>
	<DOCNO>NCT01278134</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , parallel group study evaluate safety efficacy combination RO5024048 ritonavir-boosted danoprevir without Copegus ( ribavirin ) patient chronic hepatitis C genotype 1 . In arm A B , interferon treatment-naïve patient receive 1000 mg RO5024048 orally twice daily 100 mg danoprevir 100 mg ritonavir orally twice daily plus either Copegus ( 1000 mg 1200 mg orally daily ) placebo 12 week . Depending viral response treatment arm patient re-randomized continue assign treatment additional 12 week stop treatment . The anticipated time study treatment 24 week plus 24-week follow-up . As 29 . September 2011 , Arm B patient ( placebo-containing arm ) offer , conjunction current treatment , Pegasys ( peginterferon alfa-2a ) 180 mcg subcutaneously weekly plus Copegus 1000mg 1200 mg orally daily 24 week , 24-week follow-up .</brief_summary>
	<brief_title>A Study RO5024048 Combination With Ritonavir-Boosted Danoprevir With Without Copegus ( Ribavirin ) Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 ( INFORM-SVR )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Lactams</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Chronic Hepatitis C &gt; /= 6 month duration screen HCV genotype 1 quantifiable HCV RNA screening ( Roche COBAS TaqMan HCV test ) Naïve treatment interferon ( pegylated nonpegylated ) Body Mass Index ( BMI ) 1835 inclusive , minimum weight 45 kg Females childbearing potential male female partner childbearing potential must use 2 form effective nonhormonal contraception Pregnant lactate woman male female partner pregnant lactate Decompensated liver disease impair liver function Cirrhosis incomplete/transition cirrhosis Nonhepatitis C chronic liver disease Hepatitis B HIV infection History neoplastic disease within last 5 year , except localize situ carcinoma skin History preexist renal disease ( except nephrolithiasis ) severe cardiac disease History drug alcohol abuse within last year alcohol consumption &gt; 2 unit per day ; cannabinoid use except</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>